I-BET-762 (molibresib) had been widely studied as a BRD4 Inhibitor for its therapeutic potential in various malignancies (34, 35), while TPCA-1 had been extensively used in infectious diseases for its anti-inflammatory effect. Here, BRD4 is linked to infectious disease.